Combinaison pharmacologique d'un inhibiteur de CREB et d'un agoniste de AKT pour accélérer la guérison des plaies
Utilisation de l'inhibiteur pharmacologique de la voie signalétique AKT (C646) en combinaison avec l'agoniste de la voie CREB (SC-79) pour accélérer la guérison des plaies cornéennes chez les patients
The healing of corneal injuries and cataract surgeries generally requires 5-6 days, a period during which the risk of infection increases. The group of Prof Guérin and colleagues (patent pending) has demonstrated that the modulation of CREB (inhibition by C646) and AKT (induction by SC79) signalling pathways can stimulate the growth of corneal cells, contributing to reduce the healing time to 4-5 days (rather than 6-7 days for DMSO-treated controls) using a human tissue-engineered cornea in vitro model (Couture et al., 2018).
This in vitro demonstration was reproduced in vivo in a rabbit ophtalmic injury disease model (unpublished).
Furthermore, this invention could have broad applications in wound healing using topical formulations.
Guérin S, L Germain, K Zaniolo, C Couture, and P Desjardins (2017). Compositions favoring wound repair. WO2017075715A1. Assignee: Université Laval.
Couture C, P Desjardins, K Zaniolo, L Germain, and SL Guérin (2018). Enhanced wound healing of tissue-engineered human corneas through altered phosphorylation of the CREB and AKT signal transduction pathways. Acta Biomater in press, doi: 10.1016/j.actbio.2018.04.021
A synergistic pharmacological combination of C646 and SC79 to accelerate corneal wound healing. SOVAR and Université Laval seek a partner for co-development or commercialization of this technology, in the form of more potent derivatives and/or formulation to increase the corneal residence time.
The research group is fully capable of performing in vitro and in vivo evaluation of (formulated) compounds in human tissue-engineered corneas and in rabbits.